Stock IRLAB A IRLAB THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Company IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Pharmaceuticals

Delayed Nasdaq Stockholm
Other stock markets
 03:05:29 03/05/2024 pm IST 		5-day change 1st Jan Change
10.9 SEK -2.24% Intraday chart for IRLAB Therapeutics AB -5.22% +45.33%
22/03 IRLAB Therapeutics Receives Minutes from End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program for Mesdopetam CI
19/03 IRLAB Therapeutics AB Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson's Disease Psychosis CI

Business Summary

IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

Number of employees: 31

Sales per Business

SEK in Million2021Weight2022Weight Delta
Pharmaceutical
100.0 %
208 100.0 % 61 100.0 % -70.58%

Sales per region

SEK in Million2021Weight2022Weight Delta
United Kingdom
100.0 %
208 100.0 % 61 100.0 % -70.58%

Managers

Managers TitleAgeSince
Clas Sonesson FOU
 Founder 63 01/13/01
Gunnar Olof Olsson CEO
 Chief Executive Officer 71 06/17/06
Nicholas Waters FOU
 Founder 62 01/13/01
Erik Viktor Siewertz DFI
 Director of Finance/CFO 53 01/13/01
Peder Svensson CTO
 Chief Tech/Sci/R&D Officer 62 01/16/01
Joakim Tedroff CTO
 Chief Tech/Sci/R&D Officer 63 01/16/01
Susanna Waters PRN
 Corporate Officer/Principal 58 -

Members of the board

Members of the board TitleAgeSince
Jan Anders Vedin BRD
 Director/Board Member 82 01/16/01
Rein Piir BRD
 Director/Board Member 66 01/16/01
Carola Elisabet Lemne CHM
 Chairman 66 01/19/01
Gunnar Olof Olsson CEO
 Chief Executive Officer 71 06/17/06
Christer Nordstedt BRD
 Director/Board Member 62 01/23/01
Veronica Wallin BRD
 Director/Board Member 38 01/23/01
Daniel Johnsson BRD
 Director/Board Member 56 01/23/01
Catharina Gustafsson Wallich BRD
 Director/Board Member 60 01/22/01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 79,776 0 0 57.48 %
Stock B 1 51,788,630 29,815,943 ( 57.57 %) 0

Shareholders

NameEquities%Valuation
Daniel Johnsson
8.690 %
4,500,400 8.690 % 7 M kr
Ancoria Insurance Ltd.
7.389 %
3,826,638 7.389 % 6 M kr
FV Group AB
7.078 %
3,665,626 7.078 % 5 M kr
Fjärde AP-fonden
6.749 %
3,495,420 6.749 % 5 M kr
Futur Pension Försäkringsaktiebolag
3.969 %
2,055,484 3.969 % 3 M kr
Unionen (Investment Management)
3.862 %
2,000,000 3.862 % 3 M kr
Tredje AP-fonden
3.568 %
1,847,994 3.568 % 3 M kr
Philip Diklev
2.929 %
1,517,106 2.929 % 2 M kr
Marinvest Holding AB
2.333 %
1,208,250 2.333 % 2 M kr
Hans Victor
2.033 %
1,052,699 2.033 % 2 M kr
NameEquities%Valuation
Nicholas Waters
11.21 %
8,946 11.21 % 13 052 kr
Susanna Waters
11.21 %
8,946 11.21 % 13 052 kr
Peder Svensson
11.21 %
8,946 11.21 % 13 052 kr
Cecilia Tivert Stenberg
11.21 %
8,946 11.21 % 13 052 kr
Joakim Tedroff
11.21 %
8,946 11.21 % 13 052 kr
Clas Sonesson
11.21 %
8,946 11.21 % 13 052 kr
Rein Piir
6.978 %
5,567 6.978 % 8 122 kr

Company contact information

IRLAB Therapeutics AB

Arvid Wallgrens Backe 20

413 46, Gothenburg

+46 3 17 57 38 00

http://www.irlab.se
address IRLAB Therapeutics AB(IRLAB A)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Ratings for IRLAB Therapeutics AB

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
IRLAB THERAPEUTICS AB Stock IRLAB Therapeutics AB
+45.33% 53.03M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.68% 681B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+19.30% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.35% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.65% 325B
ABBVIE INC. Stock AbbVie Inc.
+3.77% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.02% 235B
NOVARTIS AG Stock Novartis AG
+4.48% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-11.90% 189B
PFIZER, INC. Stock Pfizer, Inc.
-3.79% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. IRLAB A Stock
  4. Company IRLAB Therapeutics AB